Last reviewed · How we verify

Enamel Matrix Proteins

University of Campinas, Brazil · FDA-approved active Biologic

Enamel Matrix Proteins is a Regenerative biologic / Periodontal regenerative material Biologic drug developed by University of Campinas, Brazil. It is currently FDA-approved for Periodontal bone defects and intrabony pockets, Periodontal regeneration following scaling and root planing.

Enamel matrix proteins promote periodontal tissue regeneration by stimulating the migration, proliferation, and differentiation of periodontal ligament cells and osteoblasts.

Enamel matrix proteins promote periodontal tissue regeneration by stimulating the migration, proliferation, and differentiation of periodontal ligament cells and osteoblasts. Used for Periodontal bone defects and intrabony pockets, Periodontal regeneration following scaling and root planing.

At a glance

Generic nameEnamel Matrix Proteins
SponsorUniversity of Campinas, Brazil
Drug classRegenerative biologic / Periodontal regenerative material
ModalityBiologic
Therapeutic areaDentistry / Periodontics
PhaseFDA-approved

Mechanism of action

Enamel matrix proteins are derived from porcine tooth buds and contain amelogenins and other bioactive proteins that mimic the natural extracellular matrix signaling environment during tooth development. When applied to periodontal defects, these proteins facilitate the recruitment and activation of progenitor cells, promoting new bone formation, cementum deposition, and periodontal ligament regeneration. This biological approach restores the functional attachment apparatus lost due to periodontal disease.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Enamel Matrix Proteins

What is Enamel Matrix Proteins?

Enamel Matrix Proteins is a Regenerative biologic / Periodontal regenerative material drug developed by University of Campinas, Brazil, indicated for Periodontal bone defects and intrabony pockets, Periodontal regeneration following scaling and root planing.

How does Enamel Matrix Proteins work?

Enamel matrix proteins promote periodontal tissue regeneration by stimulating the migration, proliferation, and differentiation of periodontal ligament cells and osteoblasts.

What is Enamel Matrix Proteins used for?

Enamel Matrix Proteins is indicated for Periodontal bone defects and intrabony pockets, Periodontal regeneration following scaling and root planing.

Who makes Enamel Matrix Proteins?

Enamel Matrix Proteins is developed and marketed by University of Campinas, Brazil (see full University of Campinas, Brazil pipeline at /company/university-of-campinas-brazil).

What drug class is Enamel Matrix Proteins in?

Enamel Matrix Proteins belongs to the Regenerative biologic / Periodontal regenerative material class. See all Regenerative biologic / Periodontal regenerative material drugs at /class/regenerative-biologic-periodontal-regenerative-material.

What development phase is Enamel Matrix Proteins in?

Enamel Matrix Proteins is FDA-approved (marketed).

What are the side effects of Enamel Matrix Proteins?

Common side effects of Enamel Matrix Proteins include Transient inflammation at application site, Allergic reaction (rare, porcine-derived).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing